RA Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,088,296
| Closed | -$6.36M | – | 73 |
|
|
2022
Q4 | $6.36M | Hold |
1,088,296
| – | – | 0.13% | 55 |
|
|
2022
Q3 | $7.29M | Sell |
1,088,296
-2,218,907
| -67% | -$13.5M | 0.16% | 64 |
|
|
2022
Q2 | $13.9M | Buy |
3,307,203
+273,600
| +9% | +$1.08M | 0.37% | 53 |
|
|
2022
Q1 | $10.2M | Hold |
3,033,603
| – | – | 0.22% | 75 |
|
|
2021
Q4 | $9.56M | Hold |
3,033,603
| – | – | 0.17% | 84 |
|
|
2021
Q3 | $9.92M | Hold |
3,033,603
| – | – | 0.14% | 77 |
|
|
2021
Q2 | $12.8M | Hold |
3,033,603
| – | – | 0.21% | 65 |
|
|
2021
Q1 | $15.1M | Buy |
3,033,603
+1,210,083
| +66% | +$9.78M | 0.23% | 57 |
|
|
2020
Q4 | $23M | Sell |
1,823,520
-34,954
| -2% | -$398K | 0.32% | 54 |
|
|
2020
Q3 | $18.3M | Hold |
1,858,474
| – | – | 0.33% | 51 |
|
|
2020
Q2 | $18.5M | Hold |
1,858,474
| – | – | 0.36% | 42 |
|
|
2020
Q1 | $16.4M | Buy |
+1,858,474
| New | +$18.3M | 0.52% | 38 |
|
|
2015
Q3 | – | Sell |
-668,406
| Closed | -$9.95M | – | 67 |
|
|
2015
Q2 | $9.95M | Buy |
668,406
+8,406
| +1% | +$128K | 1% | 31 |
|
|
2015
Q1 | $10M | Buy |
+660,000
| New | +$9.21M | 0.99% | 25 |
|
RA Capital Management's CNCE Position: Q1 2023 in Review
RA Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,088,296 shares — an estimated $6.36M sold.
RA Capital Management first reported a position in CNCE in Q1 2015 and held it in 14 quarters. The position peaked at $23M in Q4 2020. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- RA Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- RA Capital Management sold 1,088,296 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $6.36M.
- RA Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2015 and held it in 14 quarters.
- RA Capital Management's Concert Pharmaceuticals, Inc. position peaked at $23M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on RA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.